10th Annual:
Reporting on the Latest Advancements and Data in IO
Immuno-Oncology 360° offered an unparalleled opportunity to hear from stakeholders representing both the science and business communities who reported on the latest data impacting IO to fight a wider range of cancers.
2024 Keynotes & VIP Speakers
Data Mining & AI Keynote:
Clinical and Translational Data to Discovery and Trial Design
Ira Mellman, PhD
Genentech
Cancer Vaccines Keynote:
What Has Worked, What Hasn't and What's Next
Margaret Callahan, MD, PhD
University of Connecticut
Cell Therapy Keynote:
Discoveries from the Clinic that Help Inform Cell Therapy
Kristen Hege, MD
Independent Board Member at Adaptimmune, Mersana & Graphite Bio
Lessons Learned to Help Advance IO
Jason Luke, MD, FACP
UPMC Hillman Cancer
Generative AI's Impact on
IO Drug Development
Alexandra Snyder, MD
Generate Bio
Public Investing in a Difficult IPO Market
Rajiv Kaul
Fidelity Investments
IO360° Delivers 3 Key Benefits
1. Access to KOLs and stakeholders in the science and business communities, reporting on cutting-edge research and trends shaping IO technology, investment, and innovation
2. Presentations featuring 100+ talks on the latest innovative research delivered by international leaders from academia, investors, and industry representatives
3. 10+ hours of networking and business development opportunities to connect with 600+ attendees who specialize in cancer immunotherapy
2024 Key Topics
Biomarkers/Assay Development
Discovery / Preclinical
Imaging Advancements
Payload Modification
Translational Science
AI Enablement for IO
Cancer Vaccines
Cell Therapy
Clinical Developments
Neoadjuvant/Adjuvant Therapy
Business and Investing Aspects
Networking and Business Opportunities
Partnering/One-on-One Meetings:
• Dedicated partnering tables to connect with fellow industry professionals, investors and KOLs
• Partnering tool to schedule partnering meetings
• Meeting times occur throughout all breaks, lunches and receptions
• Set up multiple meetings per day
• Search other attendee profiles
• Send private message to other attendees
• Dedicated partnering help desk
Scheduled Networking:
IO360° networking opportunities take place throughout the entire event including:
• Scheduled morning and afternoon breaks
• Lunches
• Reception
• Access to the Exhibit hall
• Early evening organized historical walks of downtown Brooklyn
2024 Event Features
Who Attends
Companies Attending:
• AbbVie
• Abingworth
• Amgen
• Astellas Pharma
• AstraZeneca
• Avidity Partners
• Bayer Oncology
• BioNTech
• BMS
• Boehringer Ingelheim
• City of Hope
• Daichii-Sankyo
• Fred Hutchinson Cancer Center
• Invus Group
• Janssen
• Kite Pharma
• Memorial Sloan Kettering Cancer Center
• Merck
• Moderna
• Morgan Stanley
• Mount Sinai
• MPM BioImpact
• NCI
• Novartis
• OrbiMed
• RA Capital
• Regeneron
• Stanford University
• Stifel
• Takeda
• And More!
"By bringing together groups such as scientists, investors, and experts in clinical trial design and logistics, it creates a forum where there's quite a lot of folks participating who are not traditionally talking to one another on a daily basis." - Dr Roy Baynes, Eikon Therapeutics
Bringing in the Voice of the Patient
Kelly Spill Bonito
Patient Advocate
The Personal Impact of an
Immunotherapy Trial
We were honored to welcome Kelly Spill Bonito, a stage 3 colorectal cancer survivor, who shares her extraordinary journey through an immunotherapy clinical trial, recounting how it has not only saved her life but also restored her ability to have and raise her children.
2024 Featured Speakers
Hope Rugo, MD
City of Hope
Judd Englert, MD, PhD
Amgen
Moitreyee Chatterjee-Kishore, PhD
Astellas Pharma US
Gregory Lubiniecki, MD
Merck
Olivier Rixe, MD, PhD
Daichii-Sankyo
Marisa Dolled-Filhart, PhD
BMS
Mark DeMario, MD, MPH
BioNTech US
Edith Perez, MD
Bolt Therapeutics
Shubh Goel
AstraZeneca
Robert Meehan, MD
Moderna
Sergio Quezada, PhD
University College London Cancer Institute / Achilles Therapeutics
Harpreet Singh, PhD
Immatics
Strategic Advisors